Attovia Therapeutics

Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics.

ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com.